Jieyuan Li

Learn More
BACKGROUND Tivantinib has been described as a highly selective inhibitor of MET and is currently in a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC). However, the mechanism of tivantinib anti-tumor effect has been questioned by recent studies. RESULTS We show that tivantinib indiscriminately inhibited MET dependent and(More)
  • 1